For the first quarter of 2026, Marc Casper stated, "Our revenue grew 6% to $11.01 billion." First quarter adjusted operating income grew 6% to $2.4 billion, and the Q1 adjusted operating margin was 21.8%.
Management reported they grew adjusted EPS by 6% to $5.44 per share.
First quarter cash flow from operations was $1.2 billion and free cash flow was $830 million.
Total company adjusted gross margin in the first quarter was 40.8%.
The company also deployed $3.2 billion of capital to shareholders through $3 billion of share buybacks and approximately $160 million of dividends in the first quarter.
Management highlighted their growth strategy consisting of three pillars: high-impact innovation, their trusted partner status with customers, and their unparalleled commercial engine.
During the first quarter, the company completed the acquisition of Clario for approximately $9 billion.
Marc Casper noted that Clario is a market leader in digital endpoint data solutions and described it as an outstanding strategic fit and highly complementary to their clinical research capabilities.
Thermo Fisher Scientific Inc. also formed a strategic collaboration with SHL Medical to offer fully integrated sterile fill-finish and device assembly solutions, and progressed a strategic collaboration with NVIDIA to integrate advanced AI capabilities into their laboratory technologies.
Notable first quarter product launches included the Thermo Scientific Glacios 3 Cryo-TEM, an electron microscope that features AI-enabled workflows, and the Thermo Scientific TSQ Certis Triple Quad Mass Spectrometer.
The company also introduced the Thermo Scientific Niton XL5E handheld XRF analyzer, the Gibco CTS Compleo fill and finish system, and the FluidEase Pro ClipTip electronic pipettes.
Additionally, the company opened a new Cryo-EM Drug Discovery Center in San Francisco.
For the full year 2026, management is raising their guidance on the top and bottom line.
They expect full year revenue to be in a new range of $47.3 billion to $48.1 billion, which continues to assume 3% to 4% organic revenue growth.
Adjusted earnings per share for the full year 2026 is expected to be in the range of $24.64 to $25.12.
For the second quarter of 2026, the company is assuming organic revenue growth of about 3% and expects Q2 adjusted EPS to be between $0.25 and $0.30 higher than Q1. Management estimates between $1.9 billion and $2.1 billion of net capital expenditures, approximately $660 million of net interest expense, and free cash flow in the range of $6.9 billion to $7.4 billion for the full year.